LeMaitre Vascular (LMAT)
(Real Time Quote from BATS)
$83.81 USD
+0.22 (0.26%)
Updated Aug 16, 2024 10:37 AM ET
1-Strong Buy of 5 1
D Value C Growth C Momentum C VGM
Brokerage Reports
LeMaitre Vascular, Inc. [LMAT]
Reports for Purchase
Showing records 121 - 140 ( 193 total )
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Growth Story Intact; Resuming with a Buy Rating, $38 PT
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Healthcare - Coverage Update - Healthcare Sector
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
We are placing shares of LMAT Under Review, and transferring coverage to Scott Henry, CFA due to the departure of the covering analyst.
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
We are placing shares of LMAT Under Review, and transferring coverage to Scott Henry, CFA due to the departure of the covering analyst.
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Biologics Strength, Cost Containment Drive 2Q Beat and Raise
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Light 4Q Offset by Solid 2017 Outlook; Maintain Buy
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Updating Model for Restore Flow Allografts Acquisition
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Record 3Q on Accelerated Sales Growth and Notable Margin Expansion; Buy
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
2Q Beat and Raise; Baxter Disruption is a New Tailwind
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
Solid 1Q; ProCol Acquisition Leads to Increased 2016 Growth Outlook
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: LeMaitre Vascular, Inc.
Industry: Medical - Products
ProCol Acquisition - Small but Synergistic Biologic Tuck-In
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C